Revolution Medicines, Inc. (RVMD)

Market Cap	6.94B
Revenue (ttm)	n/a
Net Income (ttm)	-600.09M
Shares Out	185.91M
EPS (ttm)	-3.58
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	811,026
Open	37.95
Previous Close	38.10
Day's Range	37.03 - 38.09
52-Week Range	29.55 - 62.40
Beta	1.46
Analysts	Strong Buy
Price Target	67.77 (+81.45%)
Earnings Date	May 7, 2025

About RVMD

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline includes RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-98...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 13, 2020
• Employees: 534
• Stock Exchange: NASDAQ
• Ticker Symbol: RVMD
• Website: https://www.revmed.com

Analyst Forecast

According to 13 analysts, the average rating for RVMD stock is "Strong Buy." The 12-month stock price forecast is $67.77, which is an increase of 81.45% from the latest price.

Price Target

$67.77

(81.45% upside)

Analyst Consensus: Strong Buy